Overview
Pontocerebellar hypoplasia type 9 (PCH9) is an extremely rare genetic brain disorder that affects the development of the brain, particularly the cerebellum (the part of the brain that controls balance and coordination) and the pons (a part of the brainstem that connects the brain to the spinal cord). Both of these structures are abnormally small (hypoplastic) from birth. PCH9 is caused by mutations in the AMPD2 gene, which plays an important role in energy metabolism within cells, particularly in the brain. Babies with PCH9 typically show signs of the condition at birth or very early in life. Common features include severe intellectual disability, very limited or absent motor development, seizures, abnormally small head size (microcephaly), and problems with muscle tone. Many affected children have difficulty feeding and may need tube feeding. Vision problems and abnormal eye movements are also frequently seen. There is currently no cure for PCH9. Treatment is supportive and focuses on managing symptoms such as seizures, feeding difficulties, and physical therapy to help with movement and comfort. The condition is progressive, meaning it tends to worsen over time. Because PCH9 is so rare, research is limited, but genetic testing has made diagnosis more accessible. Families affected by this condition benefit from a team of specialists working together to provide the best possible care and quality of life.
Also known as:
Key symptoms:
Severely small head size (microcephaly)Severe intellectual disabilitySeizures or epilepsyVery limited or no ability to sit, stand, or walkDifficulty feeding or swallowingAbnormal muscle tone (too stiff or too floppy)Abnormal eye movementsVision problemsDelayed or absent speechFailure to thrive or poor growthInvoluntary muscle movements (spasticity)Breathing difficultiesIrritability or excessive crying
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Pontocerebellar hypoplasia type 9.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Pontocerebellar hypoplasia type 9 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Pontocerebellar hypoplasia type 9.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pontocerebellar hypoplasia type 9.
Community
No community posts yet. Be the first to share your experience with Pontocerebellar hypoplasia type 9.
Start the conversation →Latest news about Pontocerebellar hypoplasia type 9
No recent news articles for Pontocerebellar hypoplasia type 9.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific AMPD2 mutation does my child have, and what does it mean for their prognosis?,What is the best approach to managing my child's seizures?,Should my child have a feeding tube, and when is the right time to consider one?,What therapies (physical, occupational, speech) would benefit my child most?,Are there any clinical trials or research studies we could participate in?,What is the risk of having another child with this condition, and should we consider genetic counseling?,When should we involve palliative care to help with symptom management and quality of life?
Common questions about Pontocerebellar hypoplasia type 9
What is Pontocerebellar hypoplasia type 9?
Pontocerebellar hypoplasia type 9 (PCH9) is an extremely rare genetic brain disorder that affects the development of the brain, particularly the cerebellum (the part of the brain that controls balance and coordination) and the pons (a part of the brainstem that connects the brain to the spinal cord). Both of these structures are abnormally small (hypoplastic) from birth. PCH9 is caused by mutations in the AMPD2 gene, which plays an important role in energy metabolism within cells, particularly in the brain. Babies with PCH9 typically show signs of the condition at birth or very early in life.
How is Pontocerebellar hypoplasia type 9 inherited?
Pontocerebellar hypoplasia type 9 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pontocerebellar hypoplasia type 9 typically begin?
Typical onset of Pontocerebellar hypoplasia type 9 is neonatal. Age of onset can vary across affected individuals.